Tumor Immunology and Immunotherapy (TII)

肿瘤免疫学和免疫治疗（TII）

• 批准号: 9326175
• 负责人: AARON P RAPOPORT
• 金额: $ 4.88万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9326175
• 关键词: Antitumor Response; Cancer Burden; Cancer Center; Cancer Center Support Grant; Cells; Clinical; Collaborations; Development; Disease; Disease Progression; Funding; Funding Agency; Goals; Immune; Immune Evasion; Immunosuppression; Infection; Inflammation; Inflammatory Response; Institution; Interdisciplinary Study; Knowledge; Malignant - descriptor; Malignant Neoplasms; Maryland; Mentors; Monitor; Nursing Faculty; Peer Review; Preventive treatment; Publications; Publishing; Research; Research Personnel; Role; Schools; Signal Transduction; Source; Translating; Treatment Protocols; Tumor Immunity; Universities; Work; base; cancer cell; cancer immunotherapy; cell growth; college; design; faculty support; falls; immunoregulation; innovation; member; neoplasm immunotherapy; novel diagnostics; novel therapeutics; prevent; programs; tumor; tumor immunology

18.0 Abstract: Tumor Immunology and Immunotherapy Program The overarching goal of the Tumor Immunology and Immunotherapy (TII) Program of UMGCC is to develop and implement immune-based strategies to prevent, treat, and/or monitor malignant diseases and disease progression. To achieve this goal, the program focuses on three specific aims: Theme 1: Cell-based cancer immunotherapies—elicit active tumor immunity capable of reducing or preventing malignant cell growth; Theme 2: Inhibiting immunosuppression—develop strategies to overcome tumor immune evasion; and Theme 3: Cancer and inflammation—elucidate the roles for infection and inflammatory responses in cancer development. The successful implementation of this work is facilitated by strong interactions between clinicians and basic researchers. Program research and mentoring strategies are designed to promote inter- and intraprogrammatic interaction and mentoring of junior research and clinical faculty. The TII program has 60 members representing 17 academic departments and 5 schools/colleges of the University of Maryland. Members of the program conduct cancer-focused research that receives $4.1 million total annual funding, including $0.6 million from NCI and $2.6 million from other peer-reviewed sources. In addition, TII Program members receive $0.9 million annually from non-peer-reviewed funding sources. Between January 2010 and December 2014, TII members authored 366 cancer-related publications, of which 21 percent resulted from intraprogrammatic and 22 percent from interprogrammatic collaborations. Approximately 52 percent of the publications represent collaborations with external investigators. Research efforts by TII faculty are supported by extensive use of the FCSS, BSS, and PBSS.

18.0摘要：肿瘤免疫学和免疫治疗方案 UMGCC肿瘤免疫学和免疫治疗(TII)计划的总体目标是开发 并实施基于免疫的策略以预防、治疗和/或监测恶性疾病和疾病 进步。为了实现这一目标，该方案侧重于三个具体目标：主题1：基于细胞的癌症 免疫疗法--激发主动的肿瘤免疫，能够减少或防止恶性细胞的生长； 主题2：抑制免疫抑制--制定克服肿瘤免疫逃避的策略；以及 主题3：癌症与炎症-阐明感染和炎症反应在癌症中的作用 发展。这项工作的成功实施是由临床医生之间的强烈互动推动的 和基础研究人员。计划研究和指导战略旨在促进相互和 初级研究和临床教师的项目内互动和指导。 TII计划有60名成员，代表17个学术部门和5所学校/学院 马里兰大学。该计划的成员进行癌症研究，获得410万美元 年度资金总额，包括来自NCI的60万美元和来自其他同行审查来源的260万美元。在……里面 此外，TII计划成员每年从非同行审查的资金来源获得90万美元。 2010年1月至2014年12月，TII成员撰写了366份与癌症有关的出版物，其中 21%来自方案内协作，22%来自方案间协作。 大约52%的出版物代表与外部调查人员的合作。研究 TII教师的努力得到了FCS、BSS和PBSS的广泛使用的支持。